Name: Suzanne Winter
New title: Chair of AdvaMed’s radiation therapy sector
Concurrent title: CEO of Accuray
Suzanne Winter, CEO of radiotherapy systems manufacturer Accuray, was named the head of AdvaMed's radiation therapy sector. She succeeds Chris Toth, group president of kidney care at Baxter and future CEO of its planned Vantive spinoff, in the role.
Winter became Accuray’s CEO in July 2022, after serving as the company’s president for a year and senior vice president and chief commercial officer before that.
AdvaMed represents radiation therapy manufacturers in the U.S. and abroad. The radiation therapy sector is among several focus areas for the trade association; others include diabetes, orthopedics and diagnostics.
Winter will lead AdvaMed’s fight against proposed cuts to Medicare and Medicaid reimbursement that the organization says will reduce patients’ access to radiotherapy, especially in rural areas. Radiation treatment, which employs high-energy beams to kill or shrink tumors, is used in about 50% to 60% of all cancer cases. AdvaMed estimates that over 1 million more lives would be saved each year if all cancer patients who needed radiation therapy could get it.
